01:25 , Nov 28, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on GDF1, MYH6 and FLT4 could help predict the risk of subtypes of congenital heart disease. Whole-exome sequencing of 2,871 congenital heart disease patients identified associations between severe disease in the Ashkenazi Jewish...
07:00 , Jul 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Myocardial infarction (MI) Myosin heavy chain 6 cardiac muscle-a (MYH6) Mouse studies suggest blocking autoimmune activity...
08:00 , Nov 7, 2011 |  BioCentury  |  Strategy

Servicing CV

While some pharmas have concluded cardiovascular disease is well served by generics and are exiting the space, Servier believes it can grow its CV business by in-licensing novel, first-in-class programs. Last month, Servier agreed to pay...
07:00 , Apr 7, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiomyopathy Myosin heavy chain 6 cardiac muscle-a (MYH6) Studies in mice and in human samples...
07:00 , Jun 16, 2008 |  BioCentury  |  Emerging Company Profile

Miragen: The heart of miRNA

Miragen: The heart of miRNA By Aaron Bouchie Senior Writer While currently approved drugs and devices to treat heart failure are palliative, Miragen Therapeutics Inc. is developing drugs against microRNA targets that it believes will be disease...